Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of AVTR101 in Sarcopenia Patients

Authors not listed

Aventi Biotechnology Inc. · 2022

Dysbiosis Human Randomized controlled trial

Abstract

The goal of this clinical trial is to primarily evaluate the efficacy of AVTR101 to placebo on physical performance in sarcopenia patients. Participants will: Take AVTR101 or a placebo three times daily for 12 weeks Visit the clinic once every 4 weeks for checkups and tests

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-22 MST

Cite this

APA

Anonymous. (2022). A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of AVTR101 in Sarcopenia Patients. <em>Aventi Biotechnology Inc.</em>. https://clinicaltrials.gov/study/NCT06788236

Vancouver

Anonymous. A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of AVTR101 in Sarcopenia Patients. Aventi Biotechnology Inc.. 2022.

BibTeX

@misc{anon2022AMulti, title = {A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of AVTR101 in Sarcopenia Patients}, author = {Anonymous}, journal = {Aventi Biotechnology Inc.}, year = {2022}, }